Galapagos NV (GLPGF)
USD 26.26
(0.0%)
USD 26.26
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 203.73 Million EUR | -58.7% |
| 2022 | 493.2 Million EUR | 2.07% |
| 2021 | 483.21 Million EUR | 1159.36% |
| 2020 | -45.61 Million EUR | -110.92% |
| 2019 | 417.66 Million EUR | 1326.99% |
| 2018 | -34.04 Million EUR | 62.76% |
| 2017 | -91.41 Million EUR | -808.97% |
| 2016 | -10.05 Million EUR | 88.84% |
| 2015 | -90.15 Million EUR | -115.97% |
| 2014 | -41.74 Million EUR | -143.3% |
| 2013 | 96.4 Million EUR | 9.43% |
| 2012 | 88.09 Million EUR | 402.73% |
| 2011 | -29.09 Million EUR | -555.1% |
| 2010 | 6.39 Million EUR | -19.99% |
| 2009 | 7.99 Million EUR | -83.76% |
| 2008 | 49.2 Million EUR | 37.57% |
| 2007 | 35.77 Million EUR | 129.02% |
| 2006 | 15.61 Million EUR | 143.63% |
| 2005 | 6.41 Million EUR | -1.2% |
| 2004 | 6.48 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 61.31 Million EUR | 2.39% |
| 2024 Q1 | 59.88 Million EUR | 120.4% |
| 2023 Q3 | 114.32 Million EUR | -21.52% |
| 2023 FY | 203.71 Million EUR | -58.7% |
| 2023 Q1 | 175.29 Million EUR | 92.68% |
| 2023 Q2 | 145.68 Million EUR | -16.89% |
| 2023 Q4 | -293.55 Million EUR | -356.76% |
| 2022 Q2 | 134.97 Million EUR | 1.15% |
| 2022 Q1 | 133.43 Million EUR | -19.63% |
| 2022 FY | 493.2 Million EUR | 2.07% |
| 2022 Q4 | 90.97 Million EUR | -32.01% |
| 2022 Q3 | 133.81 Million EUR | -0.86% |
| 2021 FY | 483.21 Million EUR | 1159.36% |
| 2021 Q2 | 813 Thousand EUR | 105.05% |
| 2021 Q4 | 166.01 Million EUR | 160.77% |
| 2021 Q3 | 63.66 Million EUR | 7730.87% |
| 2021 Q1 | -16.1 Million EUR | -223.93% |
| 2020 Q2 | -45.51 Million EUR | -144.82% |
| 2020 Q4 | 12.99 Million EUR | 3046.94% |
| 2020 FY | -45.61 Million EUR | -110.92% |
| 2020 Q1 | -18.59 Million EUR | -89.59% |
| 2020 Q3 | -441 Thousand EUR | 99.03% |
| 2019 Q2 | -35.63 Million EUR | 28.94% |
| 2019 Q1 | -50.14 Million EUR | -428.6% |
| 2019 FY | 417.66 Million EUR | 1326.99% |
| 2019 Q4 | -9.8 Million EUR | -101.91% |
| 2019 Q3 | 513.25 Million EUR | 1540.35% |
| 2018 Q2 | -32 Million EUR | -0.46% |
| 2018 Q4 | 15.26 Million EUR | 4.81% |
| 2018 FY | -34.04 Million EUR | 62.76% |
| 2018 Q3 | 14.56 Million EUR | 145.49% |
| 2018 Q1 | -31.85 Million EUR | -5.98% |
| 2017 Q2 | -21.05 Million EUR | -92.45% |
| 2017 Q1 | -10.93 Million EUR | -129.82% |
| 2017 FY | -91.41 Million EUR | -808.97% |
| 2017 Q3 | -29.36 Million EUR | -39.52% |
| 2017 Q4 | -30.06 Million EUR | -2.36% |
| 2016 Q2 | -5.91 Million EUR | 66.56% |
| 2016 Q1 | -17.69 Million EUR | 31.0% |
| 2016 Q3 | -23.11 Million EUR | -290.51% |
| 2016 FY | -10.05 Million EUR | 88.84% |
| 2016 Q4 | 36.67 Million EUR | 258.67% |
| 2015 FY | -90.15 Million EUR | -115.97% |
| 2015 Q4 | -25.64 Million EUR | 8.02% |
| 2015 Q3 | -27.88 Million EUR | -40.51% |
| 2015 Q2 | -19.84 Million EUR | -18.32% |
| 2015 Q1 | -16.77 Million EUR | -22.75% |
| 2014 FY | -41.74 Million EUR | -143.3% |
| 2014 Q4 | -13.66 Million EUR | -27.39% |
| 2014 Q3 | -10.72 Million EUR | -176.76% |
| 2014 Q1 | -3.87 Million EUR | -188.58% |
| 2014 Q2 | -3.87 Million EUR | 0.0% |
| 2013 FY | 96.4 Million EUR | 9.43% |
| 2013 Q1 | 7.51 Million EUR | 0.0% |
| 2013 Q2 | 7.51 Million EUR | 0.0% |
| 2013 Q4 | 4.37 Million EUR | 0.0% |
| 2013 Q3 | 4.37 Million EUR | -41.82% |
| 2012 Q2 | - EUR | 0.0% |
| 2012 FY | 88.09 Million EUR | 402.73% |
| 2011 FY | -29.09 Million EUR | -555.1% |
| 2011 Q2 | - EUR | 0.0% |
| 2010 Q2 | - EUR | 0.0% |
| 2010 FY | 6.39 Million EUR | -19.99% |
| 2009 Q2 | - EUR | 0.0% |
| 2009 FY | 7.99 Million EUR | -83.76% |
| 2008 FY | 49.2 Million EUR | 37.57% |
| 2007 FY | 35.77 Million EUR | 129.02% |
| 2006 FY | 15.61 Million EUR | 143.63% |
| 2005 FY | 6.41 Million EUR | -1.2% |
| 2004 FY | 6.48 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | -1258.324% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -6567759.446% |
| SQZ Biotechnologies Company | 9.79 Million USD | -1980.202% |
| Evofem Biosciences, Inc. | 11.7 Million USD | -1640.432% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | -71.051% |
| Mesoblast Limited | -35.16 Million USD | 679.319% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 596688.58% |
| Genus plc | 178.7 Million USD | -14.01% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -49571.474% |
| Marizyme, Inc. | 457.7 Thousand USD | -44412.587% |
| ContraFect Corporation | -154 Thousand USD | 132395.455% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 1852236.364% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 407570.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -265314.729% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -309866.833% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 52676.639% |
| MultiCell Technologies, Inc. | 49.32 USD | -413087896.756% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | -405.985% |
| EV Biologics, Inc. | 48.9 Thousand USD | -416535.992% |
| Q BioMed Inc. | -8988.00 USD | 2266844.548% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | -621.058% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 1320996.006% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 7.437% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -290950.0% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 164070.511% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -327311.371% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 4114296.284% |
| Arch Therapeutics, Inc. | -2439.00 USD | 8353318.532% |
| IMV Inc. | -962.29 Thousand USD | 21271.716% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -144907.117% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 209026.832% |
| GB Sciences, Inc. | -624.00 USD | 32649939.744% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 236924.057% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 97.305% |
| Halberd Corporation | -208.00 USD | 97949619.231% |
| Enzolytics Inc. | 30.7 Thousand USD | -663359.033% |
| Resverlogix Corp. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -14912.051% |
| SYBLEU INC | 11.69 Thousand USD | -1741820.315% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -42130.735% |
| argenx SE | 1.1 Billion USD | 81.62% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 889.732% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -32899.721% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 50.254% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 2300630.714% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | -359.299% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 17946.881% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -20521.348% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | -2019.811% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 243078.449% |
| BioStem Technologies, Inc. | 15.42 Million USD | -1220.823% |
| ONE Bio Corp. | 20.12 Million USD | -912.326% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 1721561.766% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 422269.958% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -115291.368% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -115291.368% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 39697.87% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | -630.13 Thousand USD | 32431.807% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 702634.483% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -45170.119% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 63865.426% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -4321.332% |
| Bioxytran, Inc. | -8285.00 USD | 2459182.68% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 54720.643% |
| Neutra Corp. | 14.33 Thousand USD | -1421141.716% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 248557.317% |
| PureTech Health plc | -1.6 Million USD | 12809.607% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 20448.349% |
| IXICO plc | 3.27 Million USD | -6130.428% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 29456.628% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 11475.489% |
| CSL Limited | 7.7 Billion USD | 97.356% |
| Cellectis S.A. | 18 Thousand USD | -1131761.111% |